Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | CACNA1H | O95180 | 7/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3620658 | 0.88 | EPHX1 (0.55) | EPHX2KDM4ECACNA1HHSD11B1ALDH1A1 | |
| SCHEMBL3620629 | 0.80 | ALDH1A1 (0.45) | EPHX2KDM4ECACNA1HALDH1A1EPHX1 | |
| SCHEMBL4741319 | 0.80 | ALDH1A1 (0.45) | EPHX2KDM4ECACNA1HALDH1A1EPHX1 | |
| SCHEMBL3617709 | 0.80 | ALDH1A1 (0.45) | EPHX2KDM4ECACNA1HALDH1A1EPHX1 | |
| SCHEMBL16395729 | 0.78 | EPHX2 (0.50) | EPHX2KDM4ECACNA1HHTTALDH1A1 | |
| SCHEMBL3622012 | 0.77 | HSD11B1 (0.61) | EPHX2HSD11B1ALDH1A1EPHX1 | |
| SCHEMBL3625180 | 0.75 | ALDH1A1 (0.51) | EPHX2KDM4ECACNA1HHSD11B1ALDH1A1 | |
| SCHEMBL4037025 | 0.74 | EPHX2 (1.00) | EPHX2KDM4EHTTHSD11B1ALDH1A1 | |
| SCHEMBL3623689 | 0.74 | HSD11B1 (0.61) | EPHX2CACNA1HHSD11B1EPHX1 | |
| SCHEMBL13002272 | 0.74 | HDAC3 (0.57) | EPHX2KDM4ECACNA1HHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2094263-B1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11 BETA-HSD1 INHIBITORS | MERCK PATENT GMBH (DE) | 2013-10-16 | — | — | EP | claimed |
| US-8183265-B2 | 2-adamantyl-butyramide derivatives as selective 11β-HSD1 inhibitors | MERCK PATENT GMBH (DE) | 2012-05-22 | — | — | US | claimed |
| US-20100022597-A1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2010-01-28 | — | — | US | claimed |
| EP-2094263-A1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11 BETA-HSD1 INHIBITORS | Merck Patent GmbH (DE) | 2009-09-02 | — | — | EP | claimed |
| WO-2008074384-A1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11βETA-HSD1 INHIBITORS | MERCK PATENT GMBH (DE) | 2008-06-26 | — | — | WO | claimed |
| EP-1935420-A1 | 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors | Merck Sante (FR) | 2008-06-25 | — | — | EP | claimed |
| EP-2094263-B1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11 BETA-HSD1 INHIBITORS | MERCK PATENT GMBH (DE) | 2013-10-16 | — | — | EP | disclosed |
| US-8183265-B2 | 2-adamantyl-butyramide derivatives as selective 11β-HSD1 inhibitors | MERCK PATENT GMBH (DE) | 2012-05-22 | — | — | US | disclosed |
| US-20100022597-A1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2010-01-28 | — | — | US | disclosed |
| EP-2094263-A1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11 BETA-HSD1 INHIBITORS | Merck Patent GmbH (DE) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008074384-A1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11βETA-HSD1 INHIBITORS | MERCK PATENT GMBH (DE) | 2008-06-26 | — | — | WO | disclosed |
| EP-1935420-A1 | 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors | Merck Sante (FR) | 2008-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022597-A1 | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | HSD11B1, HSD11B2, CYP11B1 | EPHX2 952/4885KDM4E 3280/4885CACNA1H 2447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.